Sutton Wealth Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Sutton Wealth Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-371	Closed	-$16.5K	–	1737
2022 Q2	$16.5K	Sell	371 -8	-2%	-$367	0.01%	738
2022 Q1	$18.8K	Buy	379 +6	+2%	+$288	0.01%	728
2021 Q4	$19K	Buy	373 +2	+0.5%	+$104	0.01%	715
2021 Q3	$20.7K	Hold	371	–	–	0.01%	680
2021 Q2	$15.9K	Hold	371	–	–	0.01%	772
2021 Q1	$15.5K	Hold	371	–	–	0.01%	754
2020 Q4	$17.3K	Hold	371	–	–	0.01%	657
2020 Q3	$15.8K	Hold	371	–	–	0.01%	611
2020 Q2	$17.8K	Hold	371	–	–	0.01%	570
2020 Q1	$17.1K	Hold	371	–	–	0.01%	520
2019 Q4	$22.3K	Hold	371	–	–	0.01%	561
2019 Q3	$21K	Hold	371	–	–	0.01%	568
2019 Q2	$20.7K	Hold	371	–	–	0.01%	569
2019 Q1	$18.7K	Buy	+371	New	+$16.5K	0.01%	595
2018 Q4	–	Sell	-143	Closed	-$9.91K	–	1200
2018 Q3	$9.91K	Buy	+143	New	+$10.8K	0.01%	785
2018 Q1	–	Sell	-109	Closed	-$5.82K	–	1153
2017 Q4	$5.82K	Buy	109 +22	+25%	+$1.22K	﹤0.01%	873
2017 Q3	$5.19K	Sell	87 -18	-17%	-$1.09K	﹤0.01%	870
2017 Q2	$8.28K	Hold	105	–	–	0.01%	789
2017 Q1	$8.71K	Hold	105	–	–	0.01%	746
2016 Q4	$8.33K	Hold	105	–	–	0.01%	738
2016 Q3	$7.35K	Buy	+105	New	+$5.82K	0.01%	745

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sutton Wealth Advisors's EGRX Position: Q3 2022 in Review

Sutton Wealth Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 371 shares — an estimated $16.5K sold.

Sutton Wealth Advisors first reported a position in EGRX in Q3 2016 and held it in 21 quarters. The position peaked at $22.3K in Q4 2019. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

Sutton Wealth Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Sutton Wealth Advisors sold 371 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $16.5K.
Sutton Wealth Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 21 quarters.
Sutton Wealth Advisors's Eagle Pharmaceuticals, Inc. position peaked at $22.3K in Q4 2019.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Sutton Wealth Advisors's 13F filing for Q3 2022, filed 7 Nov 2023.